New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability

Por Gumbo, Tawanda
Publicado em 2010

Anidulafungin in the treatment of invasive fungal infections

Por Sabol, Kathryn, Gumbo, Tawanda
Publicado em 2008

An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future

Por Pasipanodya, Jotam, Gumbo, Tawanda
Publicado em 2011

Reply to “Pharmacokinetic Mismatch of Tuberculosis Drugs”

Por Srivastava, Shashikant, Gumbo, Tawanda
Publicado em 2012

Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2010

A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2011

A Meta-Analysis of Self-Administered vs Directly Observed Therapy Effect on Microbiologic Failure, Relapse, and Acquired Drug Resistance in Tuberculosis Patients

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2013

Reply to Moonan and Weis, Seaworth et al, and Nunn and Phillips

Por Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado em 2013

New Susceptibility Breakpoints and the Regional Variability of MIC Distribution in Mycobacterium tuberculosis Isolates

Por Pasipanodya, Jotam, Srivastava, Shashikant, Gumbo, Tawanda
Publicado em 2012

Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study

Por Ntsekhe Mpiko, Mayosi Bongani M, Gumbo Tawanda
Publicado em 2012-07-01

Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study

Por Ntsekhe, Mpiko, Mayosi, Bongani M, Gumbo, Tawanda
Publicado em 2012

Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy

Por Pasipanodya, Jotam G., Srivastava, Shashikant, Gumbo, Tawanda
Publicado em 2012

Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease

Por Deshpande, Devyani, Pasipanodya, Jotam G., Gumbo, Tawanda
Publicado no Antimicrob Agents Chemother (2016)

Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent Advances: Insights from the Society of Infectious Diseases Pharmacists

Por Hall, Ronald G., Leff, Richard D., Gumbo, Tawanda
Publicado em 2009

Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People

Por Hall, Ronald G., Swancutt, Mark A., Gumbo, Tawanda
Publicado em 2011

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases

Por Deshpande, Devyani, Srivastava, Shashikant, Musuka, Sandirai, Gumbo, Tawanda
Publicado no Antimicrob Agents Chemother (2016)

Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead

Por Gumbo, Tawanda, Makhene, Mamodikoe K., Seddon, James A.
Publicado no Clin Infect Dis (2016)

Pharmacodynamic Evidence that Ciprofloxacin Failure against Tuberculosis Is Not Due to Poor Microbial Kill but to Rapid Emergence of Resistance

Por Gumbo, Tawanda, Louie, Arnold, Deziel, Mark R., Drusano, George L.
Publicado em 2005

Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs

Por Gumbo, Tawanda, Siyambalapitiyage Dona, Chandima S. W., Meek, Claudia, Leff, Richard
Publicado em 2009

Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium av...

Por Deshpande, Devyani, Srivastava, Shashikant, Meek, Claudia, Leff, Richard, Gumbo, Tawanda
Publicado em 2010